Exelixis, Inc. (EXEL) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended October 3, 2025 (referred to as September 30, 2025, for convenience). Exelixis is an oncology company focused on the discovery, development, and commercialization of medicines for difficult-to-treat cancers. Its revenue is primarily driven by the cabozantinib franchise (CABOMETYX and COMETRIQ) and collaboration agreements with partners such as Ipsen and Takeda. The company is advancing a pipeline including the lead asset zanzalintinib.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $597,755 | $539,542 | $1,721,463 | $1,601,946 |
| Net Product Revenues | $542,930 | $478,059 | $1,576,227 | $1,294,163 |
| Collaboration Revenues | $54,825 | $61,483 | $145,236 | $307,783 |
| Net Income | $193,578 | $117,973 | $538,042 | $381,406 |
| Diluted EPS | $0.69 | $0.40 | $1.90 | $1.28 |
| Operating Cash Flow (9M) | $550,752 | $459,708 | - | - |
| Cash & Marketable Securities | $1,566,822 | - | - | - |
| Debt | $0 | $0 | - | - |
Note: The company reported no long-term debt. Gross margin for the nine months ended September 30, 2025, was 96%.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 11% in Q3 2025 and 7% for the nine-month period compared to the prior year. Net product revenues grew 14% in Q3 and 22% for the nine months, driven by a 17% increase in CABOMETYX units sold, particularly in combination with nivolumab for renal cell carcinoma and new indications for neuroendocrine tumors.
- Collaboration Revenue Decline: Collaboration revenues decreased 11% in Q3 and 53% for the nine months. This was primarily due to a lack of large commercial milestone payments recognized in 2025 compared to a $150 million milestone recognized in the first nine months of 2024.
- Profitability: Net income increased 64% in Q3 and 41% for the nine months. This was driven by higher product sales and lower R&D expenses, partially offset by higher tax provisions and restructuring costs.
- Restructuring: The company incurred $19.8 million in restructuring expenses in Q3 2025 related to a workforce reorganization and office closure (the "2025 Plan"). This compares to $0.1 million in Q3 2024.
- Impairment: There were no impairment charges in 2025, compared to a $51.7 million non-cash impairment charge in Q3 2024 related to leased facilities.
Guidance, Outlook, and Risks
- Pipeline Progress: The company announced positive top-line results for the STELLAR-303 trial of zanzalintinib in combination with atezolizumab for metastatic colorectal cancer, showing a statistically significant improvement in overall survival. An NDA submission is planned for late 2025.
- Capital Allocation: In October 2025, the Board authorized an additional $750 million stock repurchase program through December 31, 2026. As of September 30, 2025, $104.7 million remained available under prior authorizations.
- Legal Proceedings: The company is engaged in ongoing patent litigation (Hatch-Waxman) with MSN, Sun, and Azurity regarding generic versions of CABOMETYX. A settlement with Biocon was reached in July 2025, allowing generic entry in 2031. The company notes that earlier generic entry could materially harm revenues.
- Regulatory Risks: The company faces potential pricing pressures from the Inflation Reduction Act (IRA) and potential tariffs on imported pharmaceuticals, though it currently qualifies for small biotech exceptions.
Investor Verification Checklist
- Generic Competition Timeline: Verify the status of the MSN, Sun, and Azurity litigation and the potential impact of the Biocon settlement on future CABOMETYX revenue streams.
- Zanzalintinib NDA Submission: Confirm the timing and regulatory acceptance of the planned New Drug Application for zanzalintinib in late 2025.
- Collaboration Milestone Visibility: Assess the likelihood of future milestone payments from Ipsen and Takeda to understand revenue volatility in upcoming quarters.
- Stock Repurchase Execution: Monitor the execution of the new $750 million buyback authorization and its impact on share count and liquidity.
- Restructuring Completion: Track the completion of the 2025 restructuring plan and the realization of expected cost savings.